TCJA: “Effective January 1, 2022, the Tax Cuts and Jobs Act eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States”
All entries for: Acadia Pharmaceuticals
November 3, 2023
Acadia Pharmaceuticals
Negative Outlook
San Diego, CA
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple
Drug Type: Small Molecule
August 3, 2023
Acadia Pharmaceuticals
Negative Outlook
San Diego, CA
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple
Drug Type: Small Molecule
November 2, 2022
Acadia Pharmaceuticals
Negative Outlook
San Diego, CA
10,001-50,000 employees
10001-50000 employees
EVP & CFO Mark Schneyer stated that ACAD’s increased gross-to-net adjustment (18.6% from 15.2%) is primarily due to increasing 340B volumes and “…a higher gross-to-net adjustment to account for in-channel inventory rebates associated with the inflation Reduction Act (IRA).”
Disease Area: Multiple
Drug Type: Small Molecule